NCT01976611View on ClinicalTrials.gov

Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea

CompletedOBSERVATIONAL
Enrollment

402

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Migraine DisordersHeadache
Interventions
BIOLOGICAL

botulinum toxin Type A

Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.

Trial Locations (1)

Unknown

Seoul

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01976611 - Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea | Biotech Hunter | Biotech Hunter